BioSpace News Archive

Recludix Pharma announced that in a presentation given at the 7th Annual Dermatology Drug Development Summit.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT.

ProSomnus, Inc., a leading CPAP alternative for the treatment of Obstructive Sleep Apnea, will report its third quarter financial results after market close on Thursday, November 9, 2023.

Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for felzartamab in primary membranous nephropathy (PMN).

CONMED Corporation (NYSE: CNMD) today announced that it will participate in fireside chats at the following two investor conferences in November:

DBV Technologies, a clinical-stage biopharmaceutical company, announced the receipt of written feedback from the U.S. Food and Drug Administration regarding the remaining study design elements for the COMFORT supplemental safety studies.

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, November 7, 2023 at 4:30 p.m. ET to discuss its third quarter 2023 financial results and provide a corporate update.

Cellectis announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego (CA).

OmniAb, Inc. announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:00 a.m. Eastern time.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced topline results from the Phase 2 proof-of-concept double-blind, randomized, multi-center, placebo-controlled UPLIFT study of TNX-601 ER* (tianeptine hemioxalate extended-release tablets) in patients with major depressive disorder (MDD).